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Background: Non-small cell lung cancers (NSCLC) are highly heterogeneous at the molecular level and comprise
75% of all lung tumors. We have previously shown that the receptor tyrosine kinase (RTK) MET frequently suffers
gain-of-function mutations that significantly promote lung tumorigenesis. Subsequent studies from our lab also
revealed that PAX5 transcription factor is preferentially expressed in small cell lung cancer (SCLC) and promotes
MET transcription. PAX8, however, is also expressed in NSCLC cell lines. We therefore investigated the role of
PAX8 in NSCLC.
Methods: Using IHC analysis, PAX8 protein expression was determined in archival NSCLC tumor tissues (n = 254).
In order to study the effects of PAX8 knockdown on NSCLC cellular functions such as apoptosis and motility, siRNA
against PAX8 was used. Confocal fluorescence microscopy was used to monitor the localization of MET, RON and
PAX8. The combinatorial effect of PAX8 knockdown and MET inhibition using SU11274 was investigated in NSCLC
cell viability assay.
Results: Relative levels of PAX8 protein were elevated (≥ + 2 on a scale of 0–3) in adenocarcinoma (58/94), large
cell carcinoma (50/85), squamous cell carcinoma (28/47), and metastatic NSCLC (17/28; lymph node). Utilizing early
progenitors isolated from NSCLC cell lines and fresh tumor tissues, we observed robust overexpression of PAX8,
MET, and RON. PAX8 knockdown A549 cells revealed abrogated PAX8 expression with a concomitant loss in MET
and the related RON kinase expression. A dramatic colocalization between the active form of MET (also RON) and
PAX8 upon challenging A549 cells with HGF was visualized. A similar colocalization of MET and EGL5 (PAX8
ortholog) proteins was found in embryos of C. elegans. Most importantly, knockdown of PAX8 in A549 cells resulted
in enhanced apoptosis (~6 fold) and decreased cell motility (~45%), thereby making PAX8 a potential therapeutic
target. However, the combinatorial approach of PAX8 knockdown and treatment with MET inhibitor, SU11274,
had marginal additive effect on loss of NSCLC cell viability.
Conclusion: PAX8 provides signals for growth and motility of NSCLC cells and is necessary for MET and RON
expression. Further investigations are necessary to investigate the therapeutic potential of PA8 in NSCLC.
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Lung cancer is a devastating illness with an overall survival
of 17% in NSCLC. NSCLC has differential histological clas-
sification (adeno carcinoma, squamous cell carcinoma and
large cell carcinoma) and prognosis is dependent consider-
ably on the stage of the cancer at the time of diagnosis [1].
In order to make an impact on the disease, understanding
key molecular changes is crucial. Most recently, EGFR
mutations, ALK/ROS1 translocation and MET amplifica-
tion have been shown in a subset of NSCLC [2]. A much
wider impact, however, can be achieved by investigating
the role of transcription factors, as they regulate gene
transcription programs.
PAX genes comprise a relatively small family with 9
members that are highly conserved through evolution.
They play key indispensable role in development. PAX
proteins are defined by the presence of an 128 amino
acid DNA binding domain at their amino terminal end
referred to as the, ‘Paired Domain’, which makes sequence
specific contact with DNA and regulates the transcription
of select genes. PAX genes are divided into four dif-
ferent subgroups based on the presence or absence of
additional domains such as homeodomain and octapep-
tide motif [3].
We have previously shown differential expression of
PAX5 and PAX8 in lung cancer [4]. While PAX5 is
selectively expressed in SCLC cells, the expression of
PAX8 was found mostly in NSCLC cells. We have also
shown that PAX5 positively regulates the transcription
of MET in SCLC. We therefore investigated further the
role of PAX8 in NSCLC. Under conditions of normal
development, PAX8 is expressed in the thyroid, kidneys,
some part of central nervous system, and the placenta.
In adults it is expressed in thyroid follicular cells and is
indispensable for the differentiation of thyroid cells [5].
In follicular thyroid carcinoma, PAX8 undergoes gene
rearrangement as a result of (2;3) (q13;p25) chromosomal
translocation with peroxisome proliferator-activated re-
ceptor- γ(PPARγ) [6]. Significant expression of PAX8 was
found in most carcinomas of thyroid, ovary and placenta
[7-10]. PAX8 is known to activate the transcription of
BCl2, which is an anti-apoptotic gene, and it is also in-
volved in suppression of p53 thus suggesting a role in
tumor initiation and progression [11,12].
We have previously shown that the simple soil nema-
tode, Caenorhabditis elegans, can be used as a model to
study the basic signaling pathways involved in lung can-
cer [13]. Their relatively short life cycle (~3 days), com-
pletely sequenced genome, invariant cell lineage make
them attractive in vivo models. Our previous work dem-
onstrated that the forced expression of a MET mutant,
originally discovered in human NSCLC, results in an
abnormal vulval phenotype with marked hyperplasia. In
C. elegans, PAX8 (also 2 and 5) equivalent is EGL-38,which plays an indispensable role in the hermaphrodite
egg laying process [14].
We show here that PAX8 is preferentially overexpressed
in NSCLC tumors. In NSCLC cells, upon stimulation with
HGF, we observed a strong nuclear colocalization of
PAX8 and phosphorylated MET and RON in the nucleus
and a similar colocalization was also seen in C. elegans
eggs suggesting that this soil nematode can be used a
model to study the genetics of MET/PAX8 and signaling
axis. Silencing of PAX8 resulted in a significant decrease
in not only PAX8 levels but also that of MET and RON
expression. The functional consequences of loss of PAX8
expression were decreased viability and cell motility in
NSCLC cells. Finally, treating PAX8 knockdown NSCLC
cells with the MET small molecule inhibitor (SU11274)
had no synergistic effect on the loss of cell viability. This is




NSCLC cell lines were obtained from the American Type
Culture Collection (Manassas, VA) and were cultured in
RPMI 1640 medium from Gibco/BRL supplemented with
10% (v/v) fetal bovine serum at 37°C with 5% CO2.
Antibodies and other Reagents
PAX8 and PAX2 antibodies were purchased from Abcam
(Cambridge, MA). The phospho-specific (pY1230/1234/
1235) anti- MET rabbit polyclonal and total MET mouse
antibody was from Invitrogen. EGFR, β Ron and p-Ron
antibodies were purchased from Santa cruz Biotechnology
(Santa Cruz, CA). SU11274 (3Z)-N-(3-Chlorophenyl)-3-
(3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-in-
dole-5-sulfonamide, the MET small molecule inhibitor was
from EMD Calbiochem (San Diego, CA). A set of four
different small interfering RNAs (siRNAs) specific for
PAX8 and scrambled control siRNA were purchased from
Qiagen (Cambridge, MA). Recombinant human HGF was
purchased from R & D systems (Minneapolis, MN).
Immunoblotting
Whole cell lysates were prepared using RIPA lysis buffer
(50 mM Tris (pH 8.0), 150 mM NaCl, 10% glycerol, 1%
NP-40, 0.5% Sodium deoxycholate, 0.1% SDS) containing
protease and phosphatase inhibitor cocktail. Protein
concentrations were determined by using the Bradford
Assay. Protein lysates about 80–100 ug were separated
by 7.5% SDS-PAGE under reducing conditions and trans-
ferred to PVDF membranes (Millipore, Bedford, MA).
The membranes were blocked in 5% BSA prepared in
TBST. Proteins were detected by immunoblotting using
kit from Boston Bioproducts (Worcester, MA).
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A549 cells were plated in 60 mm plates at a density of
1.5 × 105 in 10% RPMI and transfected with 100 nM
siRNA or scrambled control RNA (scRNA) using oligo-
fectamine transfection reagent according to the manu-
facture’s protocol (Life Technologies Grand Island, NY).
After 96 h incubation with siRNA, the lysates were pre-
pared using Ripa lysis buffer.
Cell viability assay
For cell viability assay A549 cells were plated in 96
well tissue culture plates at a density of 1 × 104 per
well. Each experiment was done in 12 or more repli-
cates. The next day, the cells were transfected with
PAX8 and control siRNA as described above. Cell via-
bility was determined using Alamar blue (Sigma, St.
Louis, MO), a non-toxic compound, which gets re-
duced in the cell and emits fluorescence. The amount
of reduced Alamar blue formed is proportional to meta-
bolic activity of cells. After 96 h, the cells were washed
with PBS and 100 μl fresh growth medium was added.
Alamar Blue was added to the media to get final con-
centration 10%. Plates were incubated at 37°C for 3 to
8 hours and fluorescence was measured using a plate
reader (530/590 ex/em).
Apoptosis assay
The A549 cells were plated in 60 mm plates and PAX8
was knocked down using PAX8 specific siRNA. The
percentage of apoptosis was determined by Annexin V
staining using FITC Apoptosis detection kit from BD
Biosciences (San Jose, CA) according to the manufac-
turer’s instructions.
Wound healing assay
PAX8 knock down A549 cells were trypsinized. 1 × 105
cells were replated in 24 well plates containing cell cul-
ture inserts (IBIDI, Verona, WI). The next day, the in-
serts were removed and the cells were washed with PBS
and fresh media was added. The fine scratch created by
the inserts was photographed at various time points.
Migration assay
Cell migration was determined in A549 cells transfected
with PAX8 siRNA or scrambled siRNA. After a 72 h
transfection, cells were trypsinized and replated for mi-
gration assay into Transwell chambers (BD Biosciences,
San Jose, CA) containing 500 μl serum free media at a
density of 1 × 105 cells per chamber. The chambers were
placed into wells of 24 well plate containing 500 μl
RPMI with 10% FBS as a chemo attractant. After 24 h,
the top and bottom chambers were washed twice with
PBS. The cells were then fixed in 4% paraformaldehyde
for 10 min at room temperature and washed again withPBS. After removing non-migrated cells from the top
chamber using a cotton swab, the remaining cells were
stained with Crystal violet for 30 minutes and then
rinsed thoroughly with distilled water to remove the
extra stain and dried overnight. Images of each chamber
were captured using a microscope and the migrated cells
were counted using Image J.
Tissue microarray construction and
immunohistochemistry
The procedure is similar to the one we previously used
[15]. Tissue blocks of patients with lung cancer at the
University of Chicago Medical Center (diagnosed be-
tween 1992 and 2005) were selected for the study after
obtaining appropriate institution IRB approval. Clinical
and pathological information were collected and the
database tabulated in an anonymous fashion. Samples of
tissue sections from primary tumors were identified and
1.5-mm cores of the identified tissues were punched
from the donor blocks and inserted into a recipient
block. Where available, the edge of primary tumor and
corresponding normal lung tissue were identified and
included into the tissue microarray (TMA). The TMA
was cut in 5-μm sections and immunohistochemistry
was performed as detailed below. The TMA slides were
deparaffinized in xylene and rehydrated through graded
ethanol solutions to distilled water and then washed in
Tris-buffered saline (TBS). Antigen retrieval was carried
out by heating sections in Citrate Buffer (pH = 6) for
15 min in a microwave oven. Endogenous peroxidase ac-
tivity was quenched by incubation in 3% H2O2 in
methanol for 5 min. Non-specific binding sites were
blocked using Protein Block (DAKO) for 20 min. Then
tissue sections were incubated for 1 h at room
temperature with PAX8 Goat antibody from Abcam.
This step was followed by 30 min incubation with goat
anti-mouse IgG conjugated to a horseradish peroxidase
(HRP)-labeled polymer (ImmunoDetector HRP, CA). Slides
were then developed for 5 min with 3-3’-diaminobenzidine
(DAB) chromogen, counterstained with hematoxylin, and
coverslipped. Negative controls were performed by substi-
tuting primary antibody step with non-immune mouse
immunoglobulins. Cytoplasmic and membranous staining
for each sample was quantified manually using a conven-
tional four-point pathology scoring system (0 - no staining,
1 - weak staining, 2 - moderate staining and 3 - strong
staining), and then by an Automated Cellular Imaging
System (ACIS, Chromavision, USA). These parallel me-
thods were found to have a strong positive correlation
with //r2 = 0.75// (p < 0.0001). While similar trends were
seen in manual scoring and ACIS analyses, we report only
ACIS data.
Automated measurement of immunostaining intensity
based on three related color parameters: the color defined
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of the color defined as the saturation. ACIS software was
programmed by experienced user-pathologist (MT), by
setting the color-specific thresholds, to determine the in-
tensity of brown (cytoplasmic and membranous) positivity
of cells within the outlined areas of interest. For each
TMA spot we selected representative areas of tumor
containing comparable number of cells (approximately
200–500 cells). ACIS software calculated the average in-
tensity for each region as a measure of IOD (integrated
optical density) in cytoplasmic and membranous compart-
ments. The IOD of each image (region) is given as the
average of optical densities of each molecule (pixel) within
the region. Computing of IOD is directly proportional to
the concentration of molecule recognized by the stain
according to Beer-Lambert Law. IOD is a proxy for anti-
gen content and it is calculated as intensity multiplied by
brown area in microns. For comparison purposes we nor-
malized IOD value to the entire measured area by calcu-
lating //IOD/10 μm^2//.Immunofluroscence and confocal microscopy
A549 cells were cultured in medium lacking FBS on
glass coverslips coated with poly-lysine in 6 well culture
plate overnight. The cells were then stimulated with
HGF (100 ng/ml) for 10 min. The cells were fixed and
permeabilized as previously reported [4] and incubated
with primary antibodies against p-MET, or p-RON, or
PAX8 and appropriate secondary antibodies labeled with
fluorescein (CY3 and CY5) and the samples were mounted
in vectashield.
Immunostaining of C. elegans embryos was performed
as described [16]. Wild type N2 adult worms were
placed on poly-lysine coated slides. A coverslip was over-
laid, and pressure was applied to extrude the embryos.
The slides were placed on dry ice or liquid N2 and cover-
slips were immediately removed. The worms were
fixed at −20°C in methanol for 5 min and then incu-
bated for 30 min in PBST (PBS containing 0.1% Tween
20). Worms were then washed once with PBST, incubated
in 5% nonfat dry milk, for 1 hour, washed once again
with PBST and incubated overnight at 4°C with pri-
mary antibodies. Next day the slides were washed
three times for 10 min with PBST and then incubated
with Alexafluor secondary antibodies for 1 h at room
temperature. Slides were washed once again three times
with PBST and mounted using mounting media con-
taining Dapi.Statistical analysis
Results for viability, wound healing, and migration assays
were expressed as mean ± SE. The statistical significance
between the means was measured by t-test.Results
PAX8 protein is relatively highly expressed in a variety of
NSCLCs including their metastatic forms
We have previously shown that PAX8 is preferentially
expressed in a variety of NSCLC cell lines [4]. In order
to validate the expression of PAX8 in NSCLC tumors,
we determined PAX8 protein expression using TMA
(Tissue Microarray) which represents archival NSCLC
tumor tissues and carried out IHC analysis of PAX8
expression in adeno carcinoma (n = 94), Large cell carci-
noma (85), squamous cell carcinoma (47), and meta-
static tumor tissue samples (28) are shown in Figure 1.
The various panels in Figure 1A represent PAX8 protein
expression in adeno, large cell, and squamous carcin-
omas, with representative images of increasing inten-
sities from left to right. The pie charts to the right show
the relative proportions of weak, moderate, and strong
staining in the three types of NSCLC. The bar graphs in
Figure 1B represent the above results as percentages and
the detailed data is summarized in Table 1. The intensity
of PAX8 expression increased from squamous cell car-
cinoma to large cell carcinoma to adenocarcinoma. The
highest % of negative cases was found in adeno carcinoma
(Figure 1B-C and Table 1).
In adeno carcinoma, almost 20% cases were PAX8-
nonexpressors, whereas in large cell carcinoma, only
6-7% of the cases were negative for PAX8 expression.
The 47 squamous cell carcinoma tissues examined,
however, were all positive for PAX8 protein expression.
No major differences were noted with respect to PAX8
expression when primary tumors were compared with
metastatic tumor samples (Figure 1B-C and Table 1).
PAX8 promotes expression of MET and RON receptor
tyrosine kinases
We previously showed that PAX5 was a key transcription
factor for MET transcription [4]. In order to check the
relationship between PAX8 and MET/RON levels, we
knocked down PAX8 expression using specific siRNA and
observed the effect on the levels of other PAX transcrip-
tion factors and MET and RON expression levels. As
shown in Figure 2, there was a dramatic loss in PAX8
expression only when the NSCLC cells were treated with
PAX8 specific siRNA but not with control scrambled
siRNA. The specificity of PAX8 siRNA can be appreciated
by the unaltered levels of PAX2 protein. Loss of PAX8 ex-
pression was also accompanied by a dramatic decrease in
the expression of both MET and RON but not EGFR tyro-
sine kinases. This suggests that PAX8 is a key transcrip-
tion factor for MET and RON, as was the case with PAX5.
Colocalization of PAX8 and activated MET (p-MET)
Earlier, we showed that PAX5 not only promoted MET
transcription but also colocalized with p-MET (active MET)
AB
C
Figure 1 (See legend on next page.)
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Figure 1 PAX8 protein expression in NSCLC tumor tissues. A. PAX8 staining was carried out as described in Methods. Representative
immunohistochemistry pictures of weak (+1), moderate (+2) and strong (+3) of PAX8 expression in adeno (top panel), large cell (middle) and
squamous cell (lower) carcinoma of the lung are shown. To the right of each panel, pie charts that represent PAX8 expression intensity in that
particular type of lung cancer is shown. B. The bar graph summarizes the percentage NSCLC tumors that express various amounts of PAX8
protein. C. Intensity of PAX8 protein expression in adeno, large cell and squamous NSCLC tumors is shown.
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whether PAX8 also behaved in a similar fashion in NSCLC
cells. The representative confocal images of PAX8 and
p-MET in resting and HGF stimulated NSCLC cells
are shown in Figure 3A. In untreated cells, PAX8 ex-
pression was mostly restricted to the perinuclear region
and p-MET was hardly seen. However, in HGF treated
cells, there was a sharp increase in the p-MET expression,
most of which was localized to the nucleus. Also there
was a strong colocalization of PAX8 and p-MET in the
nucleus, suggesting that they could be functionally linked.
A similar colocalization between MET related kinase
RON and PAX8 was observed (Figure 3B). In addition, we
also observed a strong colocalization of PAX8 (EGL5)
with MET and RON in C. elegans embryos (Figure 3C),
suggesting that the highly conserved association be-
tween MET, RON and PAX8 could have strong func-
tional significance.
PAX8 knockdown induces Apoptosis in A549 cells
The effect of PAX8 knock down in A549 cells on apop-
tosis was investigated using flow cytometry based analysis
after staining with Annexin V and PI and representative
results are shown in Figure 4. There was a six fold in-
crease in early apoptosis (compare bottom right quadrants
in scrambled and PAX8 siRNA panel) thereby indicating a
cell survival role for PAX8.
PAX8 promotes cell migration in NSCLC cells
Next we determined the effect of PAX8 knockdown on
wound healing, which is routinely used to measure the
cell motility - an index of metastatic potential. A549 cells
were treated with either control (scrambled) or PAX8
specific siRNA, allowed to grow to confluence in 24 well
plates with cell culture inserts, and then inserts were
removed to create a fine scratch. The closure wasTable 1 PAX8 expression in various NSCLC tumors as
evidenced from IHC analysis
Tumor type 0 1+ 2+ 3+ N case
Adenocarcinoma 19 17 35 23 94
Large carcinoma 5 30 35 15 85
Squamous cell carcinoma 0 19 27 1 47
Metastatic 2 9 11 6 28
The intensity of PAX8 expression scored for various NSCLC archival tumors
examined are shown, with 3+ being the maximum. The total number of
samples analyzed for each category is shown in the last column.documented over a period of 12 h as shown in Figure 5A.
There was a clear loss in cell motility as reflected by prom-
inent gaps in the scratches made in PAX8 knock down
plate compared to control cell monolayer. The quantita-
tive differences between control and PAX8 knockdown
cells are shown as bar graphs in Figure 5B.
We also carried out a cell migration assay using Boyden
Chamber with fetal calf serum as chemoattractant. The
dramatic decrease in cell migration in PAX8 knockdownFigure 2 Effect of PAX8 knockdown on the expression of PAX8,
PAX2, MET and RON in A549 cells. A549 cells were transfected
with scrambled and PAX8 specific siRNA at 100nM concentration.
The whole cell lysates were prepared and then immunoblotted with
anti-PAX8, anti-PAX2 antibodies. The lysates were used in parallel to
determine the MET, RON, and EGFR expressions using specific antibodies
in immunoblotting. β-actin was used as a loading control. As shown,
the knockdown of PAX8 had no effect on PAX2 levels. However




Figure 3 (See legend on next page.)
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Figure 3 MET and RON are localized to the same cellular compartment that is evolutionarily conserved. A. The colocalization of
phospho-MET (active form of MET) with PAX8 transcription factor in the peri-nuclear area with HGF stimulation. Representative confocal pictures
showing individual staining patterns for phospho–MET and PAX8 and the two merged in control (left panel) and HGF treated (right panel) in
A549 cells are shown. The cells were treated with HGF for 15 min at concentration of 100 ng/ml. B. The colocalization of phospho-RON
(active form of RON) with PAX8 transcription factor in the peri-nuclear area with HGF stimulation: Representative confocal pictures revealing staining
patterns of p-RON and PAX8 as well as their merged pictures are shown. C: Colocalization of PAX8 with MET and RON in C. elegan’s embryos.
Immunofluorescence of C. elegans was performed as described in Methods. The left panel shows representative confocal pictures of C. elegan’s
embryos stained with DAPI, PAX8, MET and merged. The right side panel shows staining with DAPI, PAX8, RON, and merged.
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representative photographs shown in Figure 5C and the
summary results shown as bar graphs in Figure 5D.
Combinatorial effect of MET inhibitor SU11274 and knock
down of PAX8 in NSCLC cells has an additive effect on
the loss of cell viability
The knock down of PAX8 had a significant but marginal
decrease in cell viability compared to controls (compare
75% Vs. 83%%). Treatment of A549 cells with small mol-
ecule inhibitor of MET, SU11274, however resulted in
an almost 50% loss in cell viability that further decreased
to 43% in PAX8 knocked down cells under comparable
conditions. This suggests that the combinatorial effect is
additive and not synergetic (Figure 6).
Discussion
PAX transcription factors usually play an indispensable
role in various developmental processes. For instance
PAX5 plays an important role in B cell development and
PAX8 has a key role in the differentiation of thyroid
epithelium [17]. However, we have previously shown that
PAX5 and PAX8 are differentially expressed in lung
cancers; while PAX5 expression is restricted to SCLC
cells, PAX8 expression is apparent more in NSCLC cell
lines [4]. Such out-of-context expression underscores
the loss of any normality in lung cancer. In this paper,
we have shown that PAX8 is functional in NSCLC and isFigure 4 Effect of PAX8 knockdown on A549 NSCLC cell apoptosis. A
siRNA at 100 nM concentration for 72 h. Apoptosis was quantified using flo
PAX8 expression on apoptosis is shown in the representative charts. Both e
apoptosis increased in PAX8 knockdown cells as shown by flow cytometryoverexpressed in a majority of NSCLCs, irrespective of
their sub-type, including their lymph node metastatic
forms. As with PAX5, there appears to be strong phys-
ical as well as a functional link between PAX8 and the
receptor tyrosine kinases MET and RON. A strong cellu-
lar colocalization between PAX8 and MET was observed
and the loss of PAX8 expression in NSCLC cells also
revealed a concomitant loss in the expression of MET
and RON receptor kinases but not EGFR. With respect
to functionality, PAX8 is very likely to significantly con-
tribute to both lung tumor growth and metastasis as
surmised from its role in cell viability and motility.
Knockdown of PAX8 resulted in a significant but modest
loss in cell viability, and further treatment with the MET
inhibitor SU11274 had only a marginal additive effect.
Under physiological conditions, PAX8 is required for
the normal development of the kidneys, thyroid gland,
and the Mullerian system [13,18,19]. Recently, a system-
atic study of more than 1100 (normal and tumor) cases
revealed that it was overexpressed in majority of the
renal, ovarian, and endometrial cancers; whereas only
one out of 100 lung cases turned out to be positive [20].
This is clearly in contrast to the findings reported here.
Our IHC analysis of archival lung tumor tissues unmistak-
ably showed that the majority of large cell carcinoma (94%),
adeno carcinoma (80%), squamous cell carcinoma (100%),
and metastatic tumors in lymph nodes (93%) were posi-
tive for PAX8 expression (n = 254). Also, overexpression549 cells were transfected with control (scramble) and PAX8 specific
w cytometry after staining with Annexin V/PI and effect of loss of




Figure 5 (See legend on next page.)
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Figure 5 Effect of PAX8 knock down on A549 NSCLC cell motility and migration. A. Wound healing assay was performed in A549 cells
transfected with control (scramble) and PAX8 specific siRNA for 72 h and then replated in 24 well plate containing cell culture inserts. The fine
scratch created by the inserts was monitored and photographed for 12 hr. Representative pictures of the degree of wound closure in A549 cells
when subjected to a scratch in control and PAX8 knock down cells at 12 hr. B. The open wound at each time point was quantified and normalized to
0 h. The experiments were done in triplicate and the average data is shown with standard error bars. C. A549 cells were transfected with either control
or PAX8 specific siRNA as described in Methods. After 96 h the cells were replated in Boyden chambers for migration assay. Migrated cells were fixed
and stained with Crystal violet. Representative images of control and PAX8 knockdown cells were captured using a microscope. D. The migrated cells
were counted using Image J. The experiments were done in triplicate and the averages with standard error bars are shown.
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prognosis [19,21]. Although site directed loss-of-function
mutants have been reported in hypothyroidism, no gain-
of-function mutants have been reported for PAX8 in any
cancers. Using genomic DNA extracts prepared from
NSCLC archival tumor tissues, we failed to see any muta-
tions in PAX8 genomic DNA (exons), while MET muta-
tions were apparent (data not shown). In 36% of follicular
thyroid cancers, there is a chromosomal translocation (2;3)
(q13;p25) resulting in the formation of PAX8-PPAR-γ
(peroxisome proliferator activated receptor-γ) fusion pro-
tein [6]. While, in vitro experiments have clearly demon-
strated the oncogenecity of the above fusion protein,
recent studies in follicular thyroid carcinoma suggest a
better prognosis in cases where the fusion protein was
found to be overexpressed [22].
The silencing of PAX8 in NSCLC cells not only
resulted in decreased levels of MET, but also that of
RON. MET and RON are family members of the recep-
tor tyrosine kinase and are important in the patho-
genesis of a number of malignancies. The synergistic
role of MET/RON is just beginning to be defined andFigure 6 The Combinatorial effect of PAX8 knockdown with
MET inhibitor (SU11724) on NSCLC cells. A549 cells were
transfected with either control or PAX8 specific siRNA. As shown
they were then treated with SU11274. The viability assay was done
using Alamar Blue. The histograms represent percentage of cell
viability with standard error bars.their inhibition appears to be more important than
inhibition of either one of the receptors. The findings
here show that MET/RON could potentially be down
regulated by decreasing expression by the PAX8. A re-
cent PAX8 silencing study using rat FLT-6 thyroid cells
revealed a total of 2815 genes modulated. A key finding
of this study was that PAX8 is the primary regulator of
thyroid morphogenesis and differentiation. In addition
to genes that play a direct role in thyroid development
and function, the authors identified several genes
regulated by PAX8 that belonged to cell proliferation,
apoptosis, tyrosine kinases, DNA replication, and anion
transport. One of the genes positively regulated by PAX8
was MET. However the decrease in MET transcripts in
PAX8 knockdown cells, although significant, was only
1.4 fold [23]. In the present study, we observed a
dramatic decrease in the protein expression levels of
MET and RON. We previously showed the presence of a
functional PAX binding site in MET (and also RON)
proximal promoter region [4]. It thus appears that PAX8
regulates the transcription of MET and RON but not
EGFR. Similar to our earlier report with respect to PAX5
[4], we also observed a strong colocalization of PAX8
with active forms of MET and RON kinases, especially
after the NSCLC cells were stimulated with HGF. The
fact that the colocalization between PAX8 and the RTKs
is conserved even in the simple nematode suggests a
strong functional link. One possibility that is being
currently tested is whether the active forms of MET and
RON as feedback inhibitors of PAX8 transcription.
We have shown here clearly that PAX8 promotes cell
motility and wound healing, a harbinger of its role in
metastasis. Most likely, the above effect is through its
ability to promote the transcription of both MET and
RON RTKs. We and others showed that both MET and
RON provide essential growth signals for lung tumor
development and also play a key role in metastasis [4]. It
is not surprising that PAX8 knockdown results in signifi-
cant loss in A549 cell viability; as such a role was dem-
onstrated for PAX transcription factors including PAX8
in the promotion of cancer cell growth [12,24,25]. In
order to rule out the vagaries of using one transformed
cell line, A549, we also repeated the functional assays
using H1993, another NSCLC cell line and investigated
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and viability. We have consistently observed that they
were similar to that shown for A549 cells. For instance,
knockdown of PAX8 in H1993 cells resulted in a loss in
the ability to close the gap created in scratch assay by
about 20% at 12 h that was comparable to that seen in
PAX8 knockdown A549 cells in relation to respective
scrambled RNA treated controls, although actual values
were somewhat different. In terms of cell viability, PAX8
knockdown had a marginal inhibitory effect in both
A549 and H1993 cells. Inhibition of MET using specific
inhibitors is also known to adversely affect NSCLC cell
viability and is the basis for several ongoing clinical tri-
als aimed at testing the efficacy of MET inhibitors in
NSCLC and other cancers [26]. Our results using
SU11274, an ATP-competitive small molecule inhibi-
tor of the catalytic activity of MET in A549 cells, clearly
support the above. However, a combinatorial approach of
using SU11274 in PAX8 knockdown background failed to
induce synergetic loss in A549 cell viability. Also in H1993
cells, it was the MET inhibitor (SU11274) that had max-
imum inhibitory effect on cell viability that was com-
parable to that observed in A549 cells. There was however
no discernible synergy on loss of cell viability when the
SU11274 was used in PAX8 knockdown H1993 cells.
These observations substantiate our contention that PAX8
knockdown effects in NSCLC cells are consistent and due
to the use of any select NSCLC cell line. The lack of
synergy can be logically explained by the fact that a loss in
PAX8 transcription factor activity results in a dramatic
loss in MET expression, thereby making the use of
SU11274 redundant, at least with respect to MET.
Synergy in killing NSCLC is more likely to be achieved by
combining PAX8 knockdown with a non-overlapping
disparate approach such as cisplatin that forms DNA
adducts [27].
Conclusion
In conclusion, we report here a potential therapeutic target
PAX8 whose silencing in NSCLC cells promotes loss in
viability and motility; most likely through the deprivation
of essential signals from METand RON RTKs.
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